1. Newsroom
  2. Frontier debt: a compelling investment opportunity
Menu
Expertise 11.03.2020

Frontier debt: a compelling investment opportunity

Frontier debt: a compelling investment opportunity

We believe frontier markets offer a compelling long-term investment opportunity: the combination of faster average growth rates, mostly manageable debt loads, and higher yields is what makes them attractive.



Historically, frontier debt has outperformed other emerging market debt sub-asset classes, as well as the US high-yield segment, due to attractive yields and relatively low default rates. Frontier debt has also proved itself to be a good diversifier in balanced portfolios.

Opportunity

The recent significant widening of high-yield sovereign spreads offers an attractive entry point into the asset class. With the Fed’s recent surprise rate cut – and as we are now well into the cutting cycle – value is slowly being eroded from fixed-income assets around the world. One of the few places left where investors can generate reasonably attractive yields is in frontier markets. Despite recent events pointing to a temporary slowdown in growth, we do not expect to see a significant impact on the broader solvency metrics for the overall asset class; rather, we expect the mean reverting nature of credit to hold true, making today’s spread levels look very attractive.

Investment philosophy and process

UBP’s Emerging Market Debt team has a long history in credit research and security selection. The investment process for the frontier strategies will focus on bottom-up selection, aiming to generate attractive carry throughout the investment cycle, while managing the risks associated with those countries in potential distress.

Our expertise

Thomas_Christiansen_150x150.jpg
Thomas Christiansen
Portfolio Manager
EM Fixed Income


A lire également

Expertise 26.11.2021

The strong performance potential of Swiss small and mid-cap equities

The Swiss small- and mid-cap (also known as “SMID-cap”) universe offers a balanced and diversified exposure to companies with long-term value-creation potential. Active managers can create significant added value through a disciplined stock-selection process.

Expertise 22.11.2021

CRISPR: the implications of gene editing

In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.

Expertise 19.11.2021

UBP Investment Outlook 2022

Embracing Change